Why the study?
It was unknown whether opening co-existing chronic total occlusions using PCI improves cardiac function in patients with multi-vessel disease.
Does opening concurrent chronic total occlusions (CTOs) using PCI improve cardiac function in patients with multi-vessel disease and CMR-detected necrotic myocardial tissue?
Does opening concurrent chronic total occlusions (CTOs) using PCI improve cardiac function in patients with multi-vessel disease and CMR-detected necrotic myocardial tissue?
Answers are grounded in this paper and cite their sources.
The SOS-moral trial will determine if concurrent PCI of chronic total occlusions improves cardiac function in patients with multi-vessel disease and myocardial necrosis.
AIMS: The purpose of the present trial is to determine whether opening co-existing chronic total occlusions (CTOs) using percutaneous coronary interventions (PCIs) improves cardiac function in patients with multi-vessel disease (MVD). Patients with MVD are defined as having at least one additional major vessel exhibiting no less than 75% stenosis combined with the presence of a CTO artery. METHODS AND RESULTS: Patients will be prospectively recruited who meet the following criteria:Patients presenting with no necrosis of myocardial tissue in the territory of the CTO will be excluded. Recruited patients will be randomized into 2 groups: those undergoing PCI of only the non-CTO artery (non-CTO PCI group), and those undergoing PCI of the non-CTO artery concurrently with the CTO artery (CTO-PCI group). The primary outcome will be the change in cardiac function evaluated via CMR at a 12-month of follow-up appointment, which will be compared to a baseline measurement. Secondary outcomes include occurrence of major cardiac events, CMR-assessed myocardial viability in the CTO-supplied territory, and quality of life assessed by Seattle angina questionnaire, Patient Health Questionnaire 9 and Generalized Anxiety Disorder Scale-7 after 12-month follow-up. CONCLUSION: The SOS-moral trial will provide data necessary to determine whether to open concurrent CTOs among MVD patients with CMR-detected necrotic myocardial tissue.
No takes yet. Share an insight, caveat, or question.
Tian et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: